Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.
PDS Biotechnology Corporation (NASDAQ: PDSB) delivers innovative immunotherapies through its Versamune® platform, targeting cancers and infectious diseases. This news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and corporate developments.
Access primary-source press releases and curated analysis covering PDSB's clinical trials, partnership announcements, and financial disclosures. Track progress across key areas: Phase II/III oncology studies, FDA communications, and strategic collaborations enhancing their nanoparticle-based therapies.
Our repository ensures you stay informed about critical developments in HPV-associated cancer treatments, combination therapy research, and infectious disease vaccine progress. Bookmark this page for direct access to PDSB's verified updates, eliminating the need to scour multiple sources.
PDS Biotechnology Corporation (PDSB) announced an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The offering is subject to market conditions, with no guarantee on completion or specific terms. Proceeds from this offering will support the development of its clinical pipeline and general corporate purposes, including working capital. The registration statement for this offering was effective as of July 31, 2020, with preliminary prospectus materials filed with the SEC.
PDS Biotechnology Corporation (Nasdaq: PDSB) will host an Oncology R&D Day on June 16, 2021, at 8:00 am ET, aimed at analysts, investors, and the scientific community. The event will showcase advancements in the company's cancer immunotherapy pipeline utilizing the proprietary Versamune® technology. Key presentations will feature several experts, including company executives and researchers from the National Cancer Institute. A live webcast will be available, along with presentations published on the company’s website the following day.
PDS Biotechnology Corporation announced interim data from its Phase 2 trial (NCT04287868) of PDS0101 (Versamune®-HPV16) at the ASCO 2021 Annual Meeting. The trial shows promising results: 83% tumor reduction in checkpoint inhibitor naïve patients and 58% in checkpoint inhibitor refractory patients. Among the 25 patients, 100% failed chemotherapy, 96% failed both chemotherapy and radiation, and 56% were checkpoint inhibitor refractory. Notably, the overall response rate compares favorably with current standards, highlighting PDS0101's potential for advanced HPV16-associated cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) will join the Russell Microcap Index effective June 28, following the annual reconstitution. This inclusion enhances the company's visibility within the investment community and offers advantages for shareholder value. The company is progressing its Phase 2 clinical programs, especially for its lead product, PDS0101, targeting HPV-associated cancers. With approximately $10.6 trillion in assets benchmarked to Russell indexes, this membership provides a significant opportunity for PDSB to attract new investments.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced an amendment to its Phase 2 VERSATILE-002 study, expanding to include checkpoint inhibitor-refractory patients with HPV-associated head and neck cancer. The study evaluates PDS0101 combined with KEYTRUDA® at around 20 US clinical sites. The trial’s new arm will assess approximately 40 patients who have previously failed treatments, aiming for improved clinical outcomes. Interim data from a related NCI trial showed a 63% objective response rate in similar patients, highlighting the potential of this therapeutic strategy.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced it will host an Oncology R&D Day on June 16th, 2021, from 8:00 – 10:00 AM ET, focusing on advancements in cancer immunotherapy. Key speakers include Dr. Frank Bedu-Addo and Dr. Lauren V. Wood. Presentations will be available on June 17th on PDS Biotech's website. Registration is open for the live webcast, which will be accessible in the investor relations section for 90 days post-event. PDS Biotech focuses on innovative immunotherapies using its Versamune technology to enhance T-cell response against cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) and the Head and Neck Cancer Alliance (HNCA) have partnered to raise awareness about treatment options for patients with HPV-attributed head and neck cancer. This collaboration aims to inform clinicians and patients about clinical trials and emerging therapies, including PDSB's leading candidate, PDS0101, which utilizes the Versamune® technology to activate T-cells against HPV-associated cancer cells. The partnership reflects an increased focus on collaborative efforts in biotechnology to improve patient outcomes in a growing cancer demographic.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced a conference call on June 8, 2021, at 8:00 am ET, following the presentation of preliminary data of PDS0101 at the 2021 ASCO Annual Meeting. The call will review data from a phase 2 trial involving PDS0101 for advanced HPV-associated cancers. Registration for the call is open, and a live webcast will be available. The full abstract and presentation will be accessible on ASCO's website and PDS Biotech's site, respectively.
PDS Biotechnology Corporation (PDSB) announced positive interim results from a phase 2 trial evaluating PDS0101 in patients with advanced HPV16-associated cancers. The trial showed an objective response rate of 71% in refractory patients, with tumor reduction observed in 83% of HPV16-positive relapsed patients who haven't previously received checkpoint inhibitors. This data will be presented at the 2021 ASCO Annual Meeting on June 7. The company’s innovative Versamune® technology is being combined with immune-modulating agents to enhance treatment efficacy.
FAQ
What is the current stock price of Pds Biotechnology Corporation (PDSB)?
What is the market cap of Pds Biotechnology Corporation (PDSB)?
